Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## CHINA LONGEVITY GROUP COMPANY LIMITED 中國龍天集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1863)

## **PROFIT WARNING**

This announcement is made by China Longevity Group Company Limited (the "Company" and together with its subsidiaries, the "Group") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors (the "Board") of the Company wishes to inform the shareholders of the Company ("Shareholders") and potential investors that, based on preliminary assessment by the Board of the latest available unaudited consolidated management accounts of the Group for the six months ended 30 June 2022 (the "Relevant Period"), the Group is expected to record a decrease in its consolidated profit attributable to the equity holders of the Company by approximately 50% to 60% as compared to a consolidated profit of approximately RMB49 million recorded in the corresponding period in 2021. The expected decrease was primarily attributable to the COVID-19 pandemic's severe impact on Chinese economy during the early half of 2022 in China and the contraction of market economies arising from the Russia-Ukraine war, which resulted in a decrease of revenue in the Group.

Despite the above unfavorable information, the Group's operating and cash flow remained stable during the Relevant Period.

The Group is still in the progress of finalising its consolidated interim results. The information contained in this announcement is only a preliminary assessment by the Board based on the latest unaudited interim consolidated management accounts of the Group, which have not been audited or reviewed by the auditor of the Company and may be subject to adjustments. Shareholders and potential investors are advised to read carefully the Company's 2022 interim results announcement for the Relevant Period, which is expected to be published by the end of August 2022.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board

China Longevity Group Company Limited

Lin Shengxiong

Chairman

Hong Kong, 23 August 2022

As at the date of this announcement, the Board of the Company comprises four Executive Directors, namely, Mr. Lin Shengxiong, Mr. Huang Wanneng, Mr. Jiang Shisheng and Mr. Liu Jun; three Independent Non-Executive Directors, namely, Mr. Lau Chun Pong, Mr. Lu Jiayu and Ms. Jiang Ping.